On March 2nd, 2015, Elwyn Specialty Care, a specialty pharmacy which is part of the Elwyn Pharmacy Group announced that it was been selected by Bayer HealthCare as one of the limited group of specialty pharmacies authorized to distribute two of the manufacturer’s oral oncology drugs—Nexavar® (sorafenib) and Stivarga® (regorafenib). As a result of being added to this exclusive network Elwyn Specialty Care is recognized as part of an elite limited group and is one of the only independently owned and operated specialty pharmacy’s included in the network.
Nexavar is an oral medication used to treat certain cancers of the thyroid, kidney and liver. In fact, the latest FDA indication is the first and only medication used to treat late-stage (metastatic) differentiated thyroid cancer, which is progressing and can no longer be treated with radioactive iodine treatment. The FDA approved Nexavar to treat advanced kidney cancer in 2005. In 2007, the agency expanded the drug’s label to treat liver cancer that cannot be surgically removed, and in late 2013, the drug was further approved to treat metastatic differentiated thyroid cancer.
Stivarga is also an oral medication used to treat a variety of gastrointestinal cancers that have spread to other parts of the body, in patients who have previously received treatment with other specific chemotherapy agents. According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer in men and in women and the third leading cause of cancer death in men and in women in the United States. Stivarga was approved by the FDA for this indication in 2012.
“At Elwyn Specialty Care we are pleased and excited to be one of the few independent specialty pharmacies accepted into this exclusive network. Providing services to the specialty oncology patients has been a passion of ours since we established our specialty pharmacy years ago. It is one of the reasons why we exist today and why we established our mission and vision as a specialty pharmacy. We feel honored to be chosen and included as part of the network”. (“Our goal is to achieve optimal patient outcomes through compliance and delivery of individualized medication therapy management in an environment that maximizes patient satisfaction and adherence”) says Nicholas Karalis, RPh, President CEO at Elwyn Pharmacy Group
About Elwyn Specialty Care also Part of The Elwyn Pharmacy Group:
At Elwyn Specialty Care we provide medications, under a comprehensive umbrella of medication therapy management, to people living with many complex disease states. We understand the complexity of managing patients’ medication and that treatment paradigms vary greatly and are highly individualized. Our patient-centered approach enables us to adapt and customize a collaborative medication therapy management plan for every patient. It is our goal to ensure treatment success and patient safety with the highest level of focus, care and compassion possible.
Elwyn Specialty Care is part of the Elwyn Pharmacy Group and provides a complete range of specialty pharmacy and infusion services. We treat a wide array of complex disease states such as Hepatitis C, Oncology/Cancer, bleeding disorders, Rheumatoid Arthritis, Psoriasis. Elwyn Specialty Care, a privately-held, pharmacist-owned company located in Garnet Valley, PA, is accredited by URAC, and the Accreditation Commission for Health Care (ACHC). For more information about Elwyn Specialty Care or Elwyn Pharmacy Group please contact us at 1-855-ELWYN-RX (359-9679) or visit us on the web at www.elwynspecialtycare.com or www.elwynpharmacygroup.com
Comments are closed.